Galápagos acquires rights to JAK inhibitor from GSK

Galápagos NV has paid an undisclosed sum to GlaxoSmithKline Plc to re-acquire rights to a candidate drug for rheumatoid arthritis which inhibits a family of enzymes known as Janus kinase (JAK). It will start a Phase 1 study on 9 August.